Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-beta (Abeta) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimers disease[1].
Molekulargewicht:
(144.8 kDa)
Reinheit:
99
CAS Nummer:
[955085-14-0]
Target-Kategorie:
Amyloid-beta
Anwendungsbeschreibung:
MCE Product type: Inhibitory Antibodies
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten